1. Home
  2. UCAR vs ERNA Comparison

UCAR vs ERNA Comparison

Compare UCAR & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.45

Market Cap

9.2M

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

N/A

Current Price

$1.16

Market Cap

10.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UCAR
ERNA
Founded
2013
2018
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
10.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
ERNA
Price
$1.45
$1.16
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
14.4K
47.2K
Earning Date
10-13-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,816,075.00
$1,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
57.22
N/A
52 Week Low
$1.43
$1.08
52 Week High
$9.43
$14.40

Technical Indicators

Market Signals
Indicator
UCAR
ERNA
Relative Strength Index (RSI) 24.03 41.30
Support Level $1.57 $1.08
Resistance Level $1.80 $1.29
Average True Range (ATR) 0.16 0.09
MACD -0.01 -0.01
Stochastic Oscillator 8.51 23.08

Price Performance

Historical Comparison
UCAR
ERNA

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Share on Social Networks: